vs
COPT DEFENSE PROPERTIES（CDP）与Esperion Therapeutics, Inc.（ESPR）财务数据对比。点击上方公司名可切换其他公司
COPT DEFENSE PROPERTIES的季度营收约是Esperion Therapeutics, Inc.的1.2倍（$197.4M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 7.6%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 1.1%）
COPT Defense Properties是一家专业房地产投资信托基金，重点投资写字楼物业，资产主要布局于华盛顿大都会区的近郊区域，核心租户为美国政府及国防军工行业企业。截至2024年12月31日，公司旗下共持有164栋写字楼，总面积达1650万平方英尺，同时运营31个单租户数据中心，总面积590万平方英尺。
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
CDP vs ESPR — 直观对比
营收规模更大
CDP
是对方的1.2倍
$168.4M
营收增速更快
ESPR
高出136.1%
7.6%
两年增速更快
ESPR
近两年复合增速
1.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $197.4M | $168.4M |
| 净利润 | $39.4M | — |
| 毛利率 | — | — |
| 营业利润率 | 19.9% | 50.6% |
| 净利率 | 20.0% | — |
| 营收同比 | 7.6% | 143.7% |
| 净利润同比 | 8.0% | — |
| 每股收益（稀释后） | $0.32 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDPESPR
| Q4 25 | $197.4M | $168.4M | ||
| Q3 25 | $188.8M | $87.3M | ||
| Q2 25 | $189.9M | $82.4M | ||
| Q1 25 | $187.9M | $65.0M | ||
| Q4 24 | $183.4M | $69.1M | ||
| Q3 24 | $189.2M | $51.6M | ||
| Q2 24 | $187.3M | $73.8M | ||
| Q1 24 | $193.3M | $137.7M |
净利润CDPESPR
| Q4 25 | $39.4M | — | ||
| Q3 25 | $43.7M | $-31.3M | ||
| Q2 25 | $40.2M | $-12.7M | ||
| Q1 25 | $36.2M | $-40.5M | ||
| Q4 24 | $36.5M | — | ||
| Q3 24 | $37.4M | $-29.5M | ||
| Q2 24 | $36.4M | $-61.9M | ||
| Q1 24 | $33.7M | $61.0M |
营业利润率CDPESPR
| Q4 25 | 19.9% | 50.6% | ||
| Q3 25 | 22.5% | -11.4% | ||
| Q2 25 | 21.0% | 8.6% | ||
| Q1 25 | 19.1% | -34.0% | ||
| Q4 24 | 19.7% | -6.4% | ||
| Q3 24 | 19.8% | -31.0% | ||
| Q2 24 | 19.4% | 3.5% | ||
| Q1 24 | 17.5% | 52.5% |
净利率CDPESPR
| Q4 25 | 20.0% | — | ||
| Q3 25 | 23.2% | -35.9% | ||
| Q2 25 | 21.1% | -15.4% | ||
| Q1 25 | 19.3% | -62.2% | ||
| Q4 24 | 19.9% | — | ||
| Q3 24 | 19.8% | -57.2% | ||
| Q2 24 | 19.4% | -83.9% | ||
| Q1 24 | 17.4% | 44.3% |
每股收益（稀释后）CDPESPR
| Q4 25 | $0.32 | $0.32 | ||
| Q3 25 | $0.37 | $-0.16 | ||
| Q2 25 | $0.34 | $-0.06 | ||
| Q1 25 | $0.31 | $-0.21 | ||
| Q4 24 | $0.31 | $-0.14 | ||
| Q3 24 | $0.32 | $-0.15 | ||
| Q2 24 | $0.31 | $-0.33 | ||
| Q1 24 | $0.29 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $275.0M | $167.9M |
| 总债务越低越好 | $2.8B | — |
| 股东权益账面价值 | $1.5B | $-302.0M |
| 总资产 | $4.7B | $465.9M |
| 负债/权益比越低杠杆越低 | 1.83× | — |
8季度趋势，按日历期对齐
现金及短期投资CDPESPR
| Q4 25 | $275.0M | $167.9M | ||
| Q3 25 | $23.7M | $92.4M | ||
| Q2 25 | $21.3M | $86.1M | ||
| Q1 25 | $24.3M | $114.6M | ||
| Q4 24 | $38.3M | $144.8M | ||
| Q3 24 | $34.5M | $144.7M | ||
| Q2 24 | $100.4M | $189.3M | ||
| Q1 24 | $123.1M | $226.6M |
总债务CDPESPR
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益CDPESPR
| Q4 25 | $1.5B | $-302.0M | ||
| Q3 25 | $1.5B | $-451.4M | ||
| Q2 25 | $1.5B | $-433.5M | ||
| Q1 25 | $1.5B | $-426.2M | ||
| Q4 24 | $1.5B | $-388.7M | ||
| Q3 24 | $1.5B | $-370.2M | ||
| Q2 24 | $1.5B | $-344.2M | ||
| Q1 24 | $1.5B | $-294.3M |
总资产CDPESPR
| Q4 25 | $4.7B | $465.9M | ||
| Q3 25 | $4.4B | $364.0M | ||
| Q2 25 | $4.3B | $347.1M | ||
| Q1 25 | $4.3B | $324.0M | ||
| Q4 24 | $4.3B | $343.8M | ||
| Q3 24 | $4.2B | $314.1M | ||
| Q2 24 | $4.2B | $352.3M | ||
| Q1 24 | $4.2B | $373.1M |
负债/权益比CDPESPR
| Q4 25 | 1.83× | — | ||
| Q3 25 | 1.62× | — | ||
| Q2 25 | 1.63× | — | ||
| Q1 25 | 1.62× | — | ||
| Q4 24 | 1.60× | — | ||
| Q3 24 | 1.61× | — | ||
| Q2 24 | 1.61× | — | ||
| Q1 24 | 1.63× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $309.9M | $45.2M |
| 自由现金流经营现金流 - 资本支出 | $288.9M | — |
| 自由现金流率自由现金流/营收 | 146.4% | — |
| 资本支出强度资本支出/营收 | 10.7% | 0.0% |
| 现金转化率经营现金流/净利润 | 7.87× | — |
| 过去12个月自由现金流最近4个季度 | $501.5M | — |
8季度趋势，按日历期对齐
经营现金流CDPESPR
| Q4 25 | $309.9M | $45.2M | ||
| Q3 25 | $68.6M | $-4.3M | ||
| Q2 25 | $87.9M | $-31.4M | ||
| Q1 25 | $72.1M | $-22.6M | ||
| Q4 24 | $331.0M | $-35.0M | ||
| Q3 24 | $65.1M | $-35.3M | ||
| Q2 24 | $93.8M | $-7.2M | ||
| Q1 24 | $71.0M | $53.8M |
自由现金流CDPESPR
| Q4 25 | $288.9M | — | ||
| Q3 25 | $62.9M | — | ||
| Q2 25 | $84.5M | — | ||
| Q1 25 | $65.1M | — | ||
| Q4 24 | $299.6M | — | ||
| Q3 24 | $61.0M | $-35.5M | ||
| Q2 24 | $88.4M | $-7.3M | ||
| Q1 24 | $57.9M | $53.8M |
自由现金流率CDPESPR
| Q4 25 | 146.4% | — | ||
| Q3 25 | 33.3% | — | ||
| Q2 25 | 44.5% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 163.3% | — | ||
| Q3 24 | 32.3% | -68.7% | ||
| Q2 24 | 47.2% | -9.9% | ||
| Q1 24 | 30.0% | 39.0% |
资本支出强度CDPESPR
| Q4 25 | 10.7% | 0.0% | ||
| Q3 25 | 3.0% | 0.0% | ||
| Q2 25 | 1.8% | 0.0% | ||
| Q1 25 | 3.7% | 0.0% | ||
| Q4 24 | 17.1% | 0.0% | ||
| Q3 24 | 2.1% | 0.3% | ||
| Q2 24 | 2.9% | 0.1% | ||
| Q1 24 | 6.8% | 0.1% |
现金转化率CDPESPR
| Q4 25 | 7.87× | — | ||
| Q3 25 | 1.57× | — | ||
| Q2 25 | 2.19× | — | ||
| Q1 25 | 1.99× | — | ||
| Q4 24 | 9.08× | — | ||
| Q3 24 | 1.74× | — | ||
| Q2 24 | 2.58× | — | ||
| Q1 24 | 2.11× | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDP
暂无分部数据
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
